For the Inventor, By the Inventor

Enter assignee name

Boston, MA, United States of America

Achillion Pharmaceuticals, Inc.

USPTO Granted Patents = 104

CIPO Patents = 1

EPO Patents = 28

Trademarks = 5

Forward Citations = 1,053

Loading Chart...

Loading Chart...

46 inventors (with patents filed for the assignee):

Avinash S Phadke (89 out of 89 patents)

Jason Allan Wiles (73 out of 80 patents)

Milind Deshpande (73 out of 77 patents)

4. Dawei Chen (70 out of 70 patents)

5. Xiangzhu Wang (69 out of 70 patents)

6. Akihiro Hashimoto (68 out of 68 patents)

7. Venkat Rao Gadhachanda (66 out of 66 patents)

8. Qiuping Wang (62 out of 62 patents)

9. Godwin Pais (61 out of 61 patents)

10. Atul Agarwal (56 out of 61 patents)

11. William J Greenlee (14 out of 155 patents)

12. Kyle J Eastman (10 out of 20 patents)

13. Suoming Zhang (10 out of 14 patents)

14. Cuixian Liu (9 out of 54 patents)

15. Joel Charles Barrish (8 out of 9 patents)

Core Competencies:

Pharmaceutical Compounds

Aryl Compounds

Heteroaryl Compounds

Heterocyclic Compounds

Macrocyclic Compounds

Immune Disorders

Inflammatory Disorders

Complement Mediated Disorders

Therapeutic Regimens

Medical Disorders

Morphic Forms

Quinazoline Compounds

104 patents: Sort by Forward Citations

1. 12479856 - Pharmaceutical compounds for the treatment of complement mediated disorders (2025-11-25),

2. 12338230 - Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders (2025-06-24),

3. 12297205 - Macrocyclic compounds for treatment of medical disorders (2025-05-13),

4. 12239645 - Targeted dosing for the treatment of complement mediated disorders (2025-03-04),

5. 12162860 - Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders (2024-12-10),

6. 12139497 - Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders (2024-11-12),

7. 12076319 - Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria (2024-09-03),

8. 12065459 - Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders (2024-08-20),

9. 12006307 - Pharmaceutical compounds for treatment of medical disorders (2024-06-11),

10. 11926617 - Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders (2024-03-12),

11. 11814391 - Macrocyclic compounds for the treatment of medical disorders (2023-11-14),

12. 11814363 - Morphic forms of danicopan (2023-11-14),

13. 11807627 - Morphic forms of complement factor D inhibitors (2023-11-07),

14. 11718626 - Macrocyclic compounds for treatment of medical disorders (2023-08-08),

15. 11708351 - Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders (2023-07-25),

Achillion Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for patients with rare diseases. We are dedicated to transforming the care of patients with complement-mediated diseases through our expertise in the complement system, a vital part of the immune system. Our pipeline includes potential treatments for diseases such as paroxysmal nocturnal hemoglobinuria (PNH), C3 glomerulopathy (C3G), and immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN).

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

104 Patents

#24 in Boston, MA

#195 in Massachusetts

#3,524 in US

#7,308 in the World

Boston, MA, United States of America

Achillion Pharmaceuticals, Inc.

Forward Citations = 1,053

46 inventors:

Avinash S Phadke (89 out of 89 patents)

Jason Allan Wiles (73 out of 80 patents)

Milind Deshpande (73 out of 77 patents)

4. Dawei Chen (70 out of 70 patents)

5. Xiangzhu Wang (69 out of 70 patents)

Please report any incorrect information to support@idiyas.com

Loading…